Citizens Raises Price Target#
Citizens has increased its price target for Celcuity Inc (NASDAQ:CELC) shares from $150 to $160. This adjustment comes as the stock currently trades at $146.60, marking an impressive 1,053% increase over the past year. However, some data suggest that the shares may be overvalued compared to their estimated fair value.
Positive Trial Results#
The price target hike follows encouraging results from Celcuity’s second Phase 3 trial for gedatolisib, a treatment for second-line ER+/HER2- advanced breast cancer. The trial demonstrated benefits for patients both with and without specific genetic mutations known as PI3K mutations. It successfully met its primary goal of improving progression-free survival, which is the length of time patients live without their disease worsening, showing statistical significance when compared to the existing treatment of alpelisib plus fulvestrant.
Increased Probability of Success#
Citizens has raised the probability of success for gedatolisib in treating advanced breast cancer with PI3K mutations from 57% to 85% based on the positive trial data. The price target is calculated using a discounted cash flow model, which estimates the value of an investment based on its expected future cash flows.
Ongoing Uncertainty and Analyst Outlook#
Despite the positive results, there remains uncertainty about whether gedatolisib meets market expectations for median progression-free survival, which is estimated to be around 11 to 12 months. Full data from the trial are expected to be presented at the upcoming ASCO conference. Other firms, including Needham and Guggenheim, have also raised their price targets for Celcuity, reflecting growing confidence in the company's recent trial outcomes.